LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Metal-on-Metal Hip Hazard Alert and Litigation Update
Legal & Regulatory and Reimbursement

Metal-on-Metal Hip Hazard Alert and Litigation Update

November 6, 2012 2 min read Premium comments

Advertisement

Metal-on-Metal Hip Hazard Alert and Litigation Update
Source: Wikimedia Commons and National Institutes of Health
Secondary

On October 26, Medsafe, New Zealand’s Medicines and Medical Devices Safety Authority noted that Zimmer Holdings, Inc.’s Durom Acetabular Cup was subject to an international hazard alert.

According to the New Zealand Joint Registry the device is no longer used in New Zealand, was discontinued by Zimmer in 2011 and was used in 252 hip implants in the country. Surgeons had been asked some months ago to carry out annual monitoring of all patients with metal-on-metal hip implants.

Garry Clark, Zimmer’s director of public relations, told OTW that in response to the ongoing public discussion on metal-on-metal articulations, “demand for these systems has declined substantially. In the majority of markets globally, Zimmer’s customers are requesting alternative products and it is no longer commercially viable for the company to offer these systems.”

In a press release, Medsafe Group Manager Dr. Stewart Jessamine says patient health is not at risk – some people will simply require their implant to be replaced earlier than expected.

“On average 90% of people with a metal-on-metal hip implant will have no problems with their implant at 10 years – a revision rate of 1.00 per 100 component years.

“For the Durom device around 84% of patients will not have problems at 10 years. The slightly higher revision rate of 1.68 per 100 component years is the reason why the product is being recalled. They do not pose any additional health risk to patients.

“There is a greater awareness by manufacturers and regulators about these devices, which is why we are seeing more of these alerts”, said Dr. Jessamine.

This, according to Medsafe, is the fifth action in New Zealand relating to the use of metal-on-metal implant components, starting with DePuy Orthopaedics’ ASR in 2010 (525 devices in New Zealand), and earlier in this year, the Mitch TR (41), the Smith and Nephew R3 (139) and the Birmingham Hip Modular Head (396).

Advertisement

FDA Action

The FDA convened a panel of independent experts this past June to review the risk of problems associated with metal-on-metal hips. The panel determined there is little, if any, benefit provided by using metal-on-metal hips. Individuals who previously received one of the systems should obtain regular examinations to check on the condition of the hip, even if they are not experiencing problems. Those who develop symptoms of pain or other complications have been urged to obtain annual blood tests for signs of metal blood poisoning.

Lawsuit Update

Thousands of lawsuits have been filed against the manufacturers (including Biomet, Inc., maker of the M2A Magnum hip not mentioned in the New Zealand action) of metal-on-metal hips. Those suits have been consolidated in various jurisdictions through multidistrict litigation (MDL) proceedings awaiting the organization and structure for the consolidated pretrial proceedings.

In addition to the Biomet MDL, at least three other MDLs have already been established for lawsuits over other metal-on-metal hip replacements that have been linked to similar problems, including the DePuy ASR hip, DePuy Pinnacle hip and Wright Medical Group, Inc.’s Conserve hip.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy